Skip to main content
TipRanks
Go Ultimate75% OFF

Nrgene (NRGN) AI Stock Analysis

0 Followers
IL:NRGN

Nrgene

(TASE:NRGN)

Select Model
Rating:52Neutral
Price Target:ILA 62.00▲(1.14% Upside)
Action:reiterated
Date:09/29/26

IL:NRGN is weighed down by severely bearish technical momentum and a lack of bottom-line profitability that pressures its valuation. However, the underlying business is showing signs of a fundamental turnaround, supported by triple-digit revenue growth, a highly de-risked balance sheet, and a recent inflection into positive free cash flow.

Positive Factors
Revenue and Gross Margin RecoveryThe sharp 2025 revenue rebound and substantial gross-margin improvement indicate stronger commercial activity and better unit economics. If maintained, this combination can improve operating leverage, support reinvestment in the platform, and provide a stronger foundation for eventual profitability.
Negative Factors
Persistent Operating and Net LossesDespite the revenue and gross-margin recovery, NRGene has not yet converted improved activity into sustainable earnings. Deeply negative EBIT and net margins indicate that operating expenses remain too high relative to gross profit, limiting internal funding capacity and weakening returns to shareholders.

Nrgene (NRGN) vs. iShares MSCI Israel ETF (EIS)

-100%-75%-50%-25%0%25%50%IL:NRGN-78.29%EIS+4.94%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
ILS 8.13M
Dividend Yield
―
Average Volume (3M)
11.38K
Price to Earnings (P/E)
-0.9
Beta (1Y)
0.59
Revenue Growth
115.63%
EPS Growth
60.19%
Country
Israel
Employees
23
Sector
Healthcare
Sector Strength
51
Industry
Software - Application

Nrgene Business Overview & Revenue Model

Company Description

NRGene Technologies Ltd is an AI-powered genomics firm that designs sophisticated computational tools and advanced algorithms, serving clients globally across North America, Europe, the Middle East, Africa, and Asia Pacific. The company provides spec...

How the Company Makes Money

NRGene primarily generates revenue by commercializing access to its genomics analysis software/platform and related services for organizations conducting genetic research and breeding programs. Key revenue streams typically include (a) software licen...

Nrgene Financial Statement Overview

Summary

A pivotal turnaround year highlighted by 251% revenue growth, a transition to positive free cash flow, and a virtually debt-free balance sheet, though constrained by lingering net losses.

Income Statement

48Neutral

Balance Sheet

68Positive

Cash Flow

75Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.25M3.17M1.29M2.00M3.16M4.46M
Gross Profit1.92M1.92M267.00K901.00K1.71M2.46M
EBITDA-1.98M-965.00K-2.69M-4.53M-5.59M-8.10M
Net Income-2.58M-1.50M-3.36M-5.24M-6.21M-8.34M
Balance Sheet
Total Assets7.12M9.54M6.00M10.79M17.30M26.36M
Cash, Cash Equivalents and Short-Term Investments3.18M5.30M1.37M6.45M12.28M22.87M
Total Debt145.02K181.00K288.00K797.00K1.61M3.34M
Total Liabilities4.66M5.13M2.00M3.57M5.04M8.68M
Stockholders Equity2.51M4.31M3.96M7.21M12.26M17.68M
Cash Flow
Free Cash Flow-511.43K72.00K-5.19M-5.58M-7.83M-6.67M
Operating Cash Flow268.11K855.00K-3.56M-3.91M-6.12M-5.57M
Investing Cash Flow364.72K455.00K-1.30M-1.27M12.47M-14.83M
Financing Cash Flow42.23K1.53M-317.00K-410.00K-2.46M27.59M

Nrgene Technical Analysis

Technical Analysis SentimentNegative
Last Price61.30

Price Trends

50DMA80.59Negative
100DMA133.66Negative
200DMA190.27Negative

Market Momentum

MACD-5.97Negative
RSI18.42Positive
STOCH65.28Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NRGN, the sentiment is Negative. The current price of 61.30 is below the 20-day moving average (MA) of 65.91, below the 50-day MA of 80.59, and below the 200-day MA of 190.27, indicating a bearish trend. The MACD of -5.97 indicates Negative momentum. The RSI at 18.42 is Positive, neither overbought nor oversold. The STOCH value of 65.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NRGN.

Nrgene Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IL:NRGN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IL:MTRXIL:MTRX68NeutralILS 10.36B20.72―3.34%36.46%16.04%
IL:NRGNIL:NRGN52NeutralILS 8.09M-0.94――115.63%60.19%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%IL:NRGNIL:MTRXIL:TECTIL:MPRSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IL:NRGN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IL:NRGNNRGENE TECHNOLOGIES LTD61.30-221.10-78.29%
IL:MTRXMatrix IT Ltd.10970.00-1747.82-13.74%
IL:TECTTECTONA LTD92.60-195.80-67.89%
IL:MPRSMediprss Pu48.50-12.50-20.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 29, 2026